EXACTLY TEN years ago, the Supreme Court of India delivered a landmark judgement on a crucial case involving under the patent protection for pharmaceuticals country's new intellectual property rights regime. It was a case that had riveted the world since the outcome had major implications for the pharma industry and for patients. It was the first test of the country's patent law, which had been amended to comply with World Trade Organization (WTO) rules, and specifically of a particular part of the law, Section 3d, which delineated what was not patentable in India. This section deals with patents for derivatives of known substances and new uses of a known substance, a hugely contested domain.
The legal challenge had come from Swiss drug giant Novartis which had filed a special leave petition (SLP) in the apex court; its final attempt to get a patent for a new form of its anti-cancer medicine Glivec after several courts had rejected the claim. The claim was for a beta crystalline version of its base compound imatinib mesylate, which had been patented much earlier. A division bench of the Supreme Court rejected the SLP and Justice Aftab Alam, who wrote the carefully nuanced judgement, laid down the fundamental reasoning for the law and its application. While the court considered the counter arguments-generic companies, patient groups and lobbyists had also filed SLPS-it was not unduly swayed by the argument for access to the medicine.
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
Trade On Emissions
EU's Carbon Border Adjustment Mechanism, a tariff on imports, is designed to protect European industries in the guise of climate action.
'The project will facilitate physical and cultural decimation of indigenous people'
The Great Nicobar Project has all the hallmarks of a disaster-seismic, ecological, human. Why did it get the go-ahead?
TASTE IT RED
Popularity of Karnataka's red jackfruit shows how biodiversity can be conserved by ensuring that communities benefit from it
MANY MYTHS OF CHIPKO
Misconceptions about the Chipko movement have overshadowed its true objectives.
The politics and economics of mpox
Africa's mpox epidemic stems from delayed responses, neglect of its health risks and the stark vaccine apartheid
Emerging risks
Even as the world gets set to eliminate substances threatening the ozone layer, climate change and space advancement pose new challenges.
JOINING THE CARBON CLUB
India's carbon market will soon be a reality, but will it fulfil its aim of reducing emissions? A report by PARTH KUMAR and MANAS AGRAWAL
Turn a new leaf
Scientists join hands to predict climate future of India's tropical forests
Festering troubles
The Democratic Republic of Congo struggles to contain mpox amid vaccine delays, conflict and fragile healthcare.
India sees unusual monsoon patterns
THE 2024 southwest monsoon has, between June 1 and September 1, led to excess rainfall in western and southern states such as Gujarat, Maharashtra and Tamil Nadu, while others like Nagaland, Manipur and Punjab recorded a deficit.